POLYCYTHEMIA VERA, POST-POLYCYTHEMIC MYELOFIBROSIS PHASE
Clinical trials for POLYCYTHEMIA VERA, POST-POLYCYTHEMIC MYELOFIBROSIS PHASE explained in plain language.
Never miss a new study
Get alerted when new POLYCYTHEMIA VERA, POST-POLYCYTHEMIC MYELOFIBROSIS PHASE trials appear
Sign up with your email to follow new studies for POLYCYTHEMIA VERA, POST-POLYCYTHEMIC MYELOFIBROSIS PHASE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug trial targets scarring bone marrow disease
Disease control OngoingThis study is testing if a drug called elotuzumab can help control myelofibrosis, a rare blood cancer that causes bone marrow scarring. The trial will involve about 15 adults with a specific genetic change (JAK2 mutation) who are not candidates for standard JAK inhibitor therapy.…
Matched conditions: POLYCYTHEMIA VERA, POST-POLYCYTHEMIC MYELOFIBROSIS PHASE
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
New Triple-Threat treatment tested for aggressive blood cancers
Disease control OngoingThis study is testing a combination of three drugs—azacitidine, venetoclax, and pevonedistat—for adults newly diagnosed with certain high-risk blood cancers. These include acute myeloid leukemia (AML) that developed from other blood disorders or prior cancer treatment, as well as…
Matched conditions: POLYCYTHEMIA VERA, POST-POLYCYTHEMIC MYELOFIBROSIS PHASE
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
Two-Pronged attack on rare blood cancers shows promise
Disease control OngoingThis study is testing whether combining two existing drugs, ruxolitinib and azacytidine, is a better treatment for people with myelofibrosis and related blood cancers. The trial enrolled 121 patients to see if this combination can improve their disease status more effectively tha…
Matched conditions: POLYCYTHEMIA VERA, POST-POLYCYTHEMIC MYELOFIBROSIS PHASE
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC